TARS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tarsus Pharmaceuticals Inc (TARS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, bullish technical indicators, positive analyst sentiment, and expanding product pipeline make it a compelling choice. Despite minor pre-market price declines and a slight net loss, the long-term growth potential outweighs these concerns.
The stock is showing bullish momentum with a positive MACD histogram (1.775), RSI in the neutral zone (75.938), and moving averages indicating an upward trend (SMA_5 > SMA_20 > SMA_200). The stock is trading near its first resistance level (R1: 76.792), suggesting potential for further upward movement.
Analysts have raised price targets significantly, with Oppenheimer projecting $105 and Guggenheim and BofA targeting $90, citing strong sales growth and market penetration.
Hedge funds are aggressively buying, with a 987.14% increase in buying activity over the last quarter.
The company achieved 128% YoY revenue growth in Q4 2025 and plans to expand its product offerings and market reach in Europe and China.
Clinical trials for new products (TP-04 and TP-
offer additional growth opportunities.
Pre-market price is down slightly by 0.66%, which may indicate short-term volatility.
The company reported a net loss of $8.37 million in Q4 2025, although this was an improvement YoY.
EPS dropped by 66.67% YoY, which may concern some investors.
Tarsus Pharmaceuticals reported Q4 2025 revenue of $151.67 million, up 128.39% YoY, driven by strong demand for XDEMVY. Gross margin increased slightly to 92.8%, but net income fell to -$8.37 million, reflecting higher R&D spending. EPS dropped to -$0.20, down 66.67% YoY. Despite these losses, the company's robust revenue growth and market expansion plans highlight its long-term potential.
Analysts are overwhelmingly positive, with multiple firms raising price targets and maintaining Buy or Outperform ratings. Oppenheimer sees potential for $2B in peak U.S. sales for XDEMVY, and Guggenheim highlights the company's strong positioning in a large, underpenetrated market. Goldman Sachs is neutral with a lower price target of $68, but this is an outlier among otherwise bullish ratings.
